ライフサイエンスコーパス: placenta growth factor

1 these findings, the VEGFR-1-specific ligand placenta growth factor-1 activated phosphatidylinositol

2 To determine the VEGF(165) and placenta growth factor 2 (PlGF-2)-binding sites of NRP1,

3 The neuropilin-1 ligand placenta growth factor-2 failed to reproduce the protect

4 ynamic biomarkers, such as changes in plasma placenta growth factor and sVEGFR2.

5 nt with an Flt-1 neutralizing antibody or by placenta growth factor but not with an Flk-1 neutralizin

6 Placenta growth factor concentration was significantly l

7 By contrast, tissue levels of placenta growth factor decreased.

8 (GM-CSF), stromal derived factor 1alpha, and placenta growth factor], G-CSF and the G-CSF-induced Bv8

9 Our studies show that placenta growth factor levels are high in SCD, and place

10 mically, cediranib increased plasma VEGF and placenta growth factor levels, and the number of circula

11 not detected in response to stimulation with placenta growth factor or an Flt-1-selective VEGF mutant

12 evels of vascular endothelial growth factor, placenta growth factor, or soluble endoglin as assessed

13 line of greater than 20% in plasma levels of placenta growth factor (P = .056), squamous cell carcino

14 vestigate the in vivo angiogenic activity of placenta growth factor (PIGF) and its heterodimers with

15 This binding was efficiently competed by placenta growth factor (PIGF), a ligand reportedly speci

16 o vascular endothelial growth factor (VEGF), placenta growth factor (PIGF-1 and PIGF-2), or basic fib

17 Our studies showed that placenta growth factor (PlGF) activated monocytes and in

18 cessive production of the angiogenic protein placenta growth factor (PlGF) and high estimated pulmona

19 ecently reported that treatment with an anti-placenta growth factor (PlGF) antibody inhibits metastas

20 We hypothesize that VEGF and placenta growth factor (PlGF) are dysregulated in preecl

21 Previous studies showed that high levels of placenta growth factor (PlGF) correlated with increased

22 , apoptosis, autophagy and emphysema-related placenta growth factor (PlGF) expressions.

23 The role of placenta growth factor (PlGF) in pathologic angiogenesis

24 reviously, we showed that elevated levels of placenta growth factor (PlGF) in SCA patients correlate

25 ascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) in the VEGF/PDGF gene fami

26 Placenta growth factor (PlGF) is a mitogen for endotheli

27 Placenta growth factor (PlGF) is an additional ligand fo

28 Placenta growth factor (PlGF) is released by immature er

29 ammation, whereas blockade of either VEGF or placenta growth factor (PlGF) signaling did not affect t

30 Placenta growth factor (PlGF) stimulated robust angiogen

31 GF), soluble VEGF receptor 1 (sVEGFR-1), and placenta growth factor (PlGF) were measured by enzyme-li

32 We previously demonstrated that placenta growth factor (PlGF), an angiogenic factor prod

33 We found that erythroid cells produced placenta growth factor (PlGF), an angiogenic growth fact

34 We hypothesized that placenta growth factor (PlGF), an erythroblast-secreted

35 s vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), and platelet-derived endo

36 VEGF-B is closely related to VEGF-A and placenta growth factor (PlGF), but unlike VEGF-A, which

37 Placenta growth factor (PlGF), elaborated from erythroid

38 Placenta growth factor (PlGF), elaborated from erythroid

39 d that VEGF-A or VEGF-E, but not VEGF-B, nor placenta growth factor (PlGF), induces the phosphorylati

40 Placenta growth factor (PlGF), released at high levels b

41 previous studies show that higher levels of placenta growth factor (PlGF), secreted by erythroid pre

42 eviously showed that erythroid cells produce placenta growth factor (PlGF), which activates monocytes

43 ascular endothelial growth factor (VEGF) and placenta growth factor (PlGF).

44 binding to their ligands, including VEGF and placenta growth factor (PlGF).

45 Flt-1 has an alternative ligand, placenta growth factor (PlGF).

46 t the Escherichia coli expressed monomers of placenta growth factor (PLGF)129 and vascular endothelia

47 ot bind to VEGF121 or the smaller isoform of placenta growth factor (PlGF129), and show reduced, but

48 were evaluated after administration of PEDF, placenta growth factor (VEGF-R1 agonist), and VEGF-E (VE

49 Placenta growth factor, which binds to Flt-1/VEGF-R1 but

50 We found that placenta growth factor, which selectively activates VEGF